Morning, everyone. Thank you for coming today. At UBS, we are very excited to host this conference here in London as our inaugural Global Biopharma Conference. We are excited that in this second day, we have even more investors, even more turnout, corporates coming in. Looking forward to another great day of meeting folks and having discussions and presentations like this one. I am excited to introduce Velaris Therapeutics, and specifically Michael Henderson as Chief Executive Officer, and Carl Dambkowski as Head of Research and Development.
Great. Thanks very much for the opportunity. For those of you that are not in the room, it is a hard transition because there was some very nice upbeat techno music, like the UBS house music, I guess, right before this. Now you get to hear us, so we will try to keep the beats going. No, thank you for the opportunity to be here and for attending. Really excited to tell you about Velaris Therapeutics today. We will be making a number of forward-looking statements throughout this, as you should expect. Velaris is developing really a strategy and pipeline for some of the largest cardiopulmonary conditions out there. Specifically, PAH, pulmonary hypertension, group two heart disease, right, HFpEF, heart failure with preserved ejection fraction due to pulmonary hypertension, and group three lung diseases.
Think pulmonary hypertension, ILD, IPF, and a number of potential blockbuster expansions, which we will get into. This is really born out of the insight that there is an incredible mechanism and activin biology that sotatercept, now Winrevair, which Merck acquired Acceleron for, has proven remarkably effective in PAH. Recent data in heart failure is also quite strong. However, right, similar to many first-in-class drugs, hindsight is 20/20, we think that there are ways that we can improve upon that first-in-class precedent in terms of clinical strategy, dose optimization, and also just bringing combinations via a wholly owned pipeline to these diseases in a way that nobody else can because they do not have all these mechanisms.
Not only are we advancing our lead, VLR199, which binds similarly to how sotatercept binds within PAH and these indications, we are also bringing a PDGFB antibody into the clinic next year alongside our lead VLR199, and that could be a mono with combination potential. There are a number of next-generation approaches that spare BMP-9/10 that others have pursued that we have unique insights that we are advancing forward as well, and that is VLR247 and VLR258. Kind of a number of layers of value creation in some of the largest, least competitive markets that are out there in quite severe conditions that we are very excited to share more about. A bit more about Winrevair. It has been a somewhat under-the-radar launch, just, right, Merck has a lot going on, which is fair.
But doing $2 billion in its second year in PAH alone, on track to be about $8 billion in PAH alone. I think that this sets us up to be potentially one of the largest new classes out there. Again, with high unmet need and very little competition. Nobody's really tracking behind Winrevair with positive data yet. To put this into context, you can see in the dark blue on the left, this $8 billion in peak is in the smallest potential indication we think that we could bring to bear. Heart failure, specifically HFpEF, Merck just put out a very nice hazard ratio of 0.18 in heart failure, which has not really been seen, right? Heart failure right now is mostly failure, so really striking results. This was only at the low dose, though. The high dose underperformed, which again speaks to the need for dose optimization.
We're excited to follow them in heart failure and do some more dose optimization. On the right, you can see four different lung indications where we believe we have a potential to be first in class by being first movers for reasons that we can get into, dynamics that work in our favor. A number of PAH drugs have gone into these respiratory conditions and done quite well, right? United Therapeutics with Tyvaso, right, kind of a number of blockbuster expansions there. Recently, Roivant with a drug that had been shelved for PAH going into PH-ILD with really remarkable phase II data, which was rewarded by the market. So, a nice precedented path that we also would plan to pursue. I'll hand it off to Carl now to talk a bit more about the biology and our drugs in particular.
Yeah. Thanks, Michael. One of the reasons we really believe there's this ability to expand beyond just PAH and HFpEF is that there's shared pathophysiology across these groups of pulmonary hypertension, group one being PAH, group two being cardiac-related ones, specifically HFpEF, and group three being lung-related diseases. That shared pathophysiology is really on the remodeling that happens at the pulmonary arterioles. What SOTA has done really well is figure out the balance between that remodeling too, between the pro-proliferative and the anti-proliferative ligands. In terms of the design of VLR199, which is the SOTA-like pipeline product we're developing too, we really tried to replicate the pharmacology of SOTA.
The reason for that is it captures a lot of ligands, not just a single target here, and the balance between capturing all those ligands we think is really important and is the reason for the efficacy that's being seen there. As Michael said, that efficacy is really best in class for pulmonary arterial hypertension, right? Looking at hazard ratios of 0.2 or less for clinical worsening across multiple indications now too. We've tried to, you can see on the right-hand side of the slides for those following along, right, you can see that that balance is something we've been able to achieve in terms of similarity between Winrevair, SOTA, and our lead VLR199.
As Michael said, there's a lot of areas where we think that they haven't completely optimized in terms of the path forward, which we'll talk about moving forward, and there's this ability to go beyond just PAH in terms of HFpEF. We're seeing really strong phase II data from Winrevair, ILD, where there is a really strong emerging case series. People are using this off-label and seeing very similar results to, if not even slightly improved to PAH alone. Then finally, multiple expansions beyond that, COPD, PPF, and other indications as well. We think that there's not only a PAH case here to be made, but a wide expansion opportunity that we can build on as well. For PAH specifically and how we plan to move there, we'll start off with a phase I study, specifically here in postmenopausal women.
The reason for that is one of the things that we can see in the phase I study is dose-dependent, predictable changes in FSH. That's on target for activin inhibition there, and really, that'll help us set up for phase I proof of concept data in first half of 2028. We'll be able to see these biomarker changes. Postmenopausal women will help us enrich for high baseline FSH, so we can see similar changes to what Winrevair saw. Really designing a phase I related to that. Then moving forward, we'll want to dose optimize here. I think one of the places that is underappreciated in terms of Winrevair is what is the right dose and our ability to improve on that. It's a Q3W dosing schedule where they only tested two doses in their phase II study.
I think there's room there to get better in terms of not only moving potentially from Q3W to Q4 week dosing, but also finding what is the truly optimized dose there and testing more than just those two regimens before moving to registrational approaches in PAH and potentially other indications. As mentioned, the phase I study for SOTA showed really nice dose-dependent changes across a variety of biomarkers. On the left-hand side here, we're showing that FSH change, but it doesn't just stop there. FSH is one of those. Bone biomarkers was another, and hemoglobin changes is a third that we can really look for there. That will allow us to really understand the pharmacology between our drug in the clinic as well as SOTA and pick the right doses to move forward in phase II planning.
The phase II, as mentioned a couple times, we really want to optimize the dose. As we look at the Winrevair data, obviously they've gone forward with 0.7, but I actually think it's a really mixed picture on whether that is the optimized dose or not. In their phase II study, they saw better PVR changes with 0.7, but no other endpoints, biomarkers, or six-minute walk tests really showed a differentiation in 0.7, and the 0.7 versus the 0.3 dose. The AE profile between 0.7 and 0.3 showed about 20%, two to three times worse hemoglobin, clinically significant heme changes with 0.7 than 0.3. So we think there's a lot of room there to understand more about what that benefit-risk trade-off is for 0.7 and 0.3 equivalent doses, but also potentially a dose in between those two. Then for phase III, we have a precedented regulatory pathway here.
We think that is really important, but I think there are areas to improve on here in terms of line of treatment. SOTA is doing quite well, as Michael had mentioned too, but getting into earlier lines of treatment is an area we can really potentially improve as well.
Looking again beyond PAH, which, right, $8 billion indication, I think a ton of momentum from Merck there, ways that we can clearly improve. Just to put it into context, right, heart failure, approximately 10x the number of potential patients, and again, a hazard ratio which was quite strong. Merck is now moving into phase III just with a single dose, right, no titration. We look to kind of learn from that and see what we can optimize. In these different lung diseases, not only do we think that this is an interesting idea, docs typically get there first.
Docs are already using SOTA across a number of these different indications, and we will get into some of this data, but very convincing signal worthy of a proper experiment now in ILD, also in PH-COPD, very high unmet need, where other COPD drugs do not drive any benefit. IPF and PPF also really precedent pathways from other PH drugs. Excited to kind of try this. Just to put HFpEF a bit more in context, on the left, you can see the data that SOTA put up in PAH, hazard ratio of 0.16. Then in the middle, you can see that hazard ratio of 0.18 that we alluded to in heart failure, right? I think quite a convincing signal. It is a phase II study. This was only in the 0.3 dose, as Carl mentioned. 0.7, they did not show a strong benefit.
They are just moving forward with that 0.3 dose, likely because the 0.7 caused too much time off drug, given the lack of tolerability. Clear room to improve there. Right, HFpEF is not the same as PH, deserves its own. They deserve just some dose optimization studies. Winrevair, though, I think it is, to their credit, the only PH drug that has worked in PH-HFpEF, which I think activin signaling, it is not just kind of vasodilating the arteries. It is actually changing the vasculature and rebalancing that signal so that you can treat the disease much closer to its source versus just symptomatic. In terms of this pathway, PH drugs, they do have an established path in PH-ILD and other pulmonary fibrosis. Tyvaso, right, a quite common prostacyclin, not the most effective drug in PH, especially if you compare the hazard ratio that they have compared to Winrevair.
However, doing quite well in PH-ILD, with FDA approval and now blockbuster status, in that indication just a few years in. A number of positive IPF phase IIIs, and they are ongoing in PPF. Roivant took mosliciguat, I cannot say the full name, did quite well in their ILD study. Speaking of the regulatory pathway, already into their phase III. I will hand it off to Carl to talk a bit more about kind of the group three signal that has been seen.
Yeah, as mentioned earlier, there is emerging data really from case series. Michael said docs using this first, on Winrevair in group three pulmonary hypertension, so lung-related pulmonary hypertension. Across endpoints, what you can see, and these are small case series right now, but what you can see is as good, if not better, results for things like six-minute walk tests, PVR, and BNP. Really, PVR and BNP specifically really have no placebo-related changes that we would be worried about seeing with those. So those feel very strong in terms of the results and the translatability moving forward as well too. So here is an area where Merck is not yet pursuing, does not seem to necessarily have any intentions to pursue at this point in time, where we think we can move rapidly and differentiate in these diseases.
Yeah, we are not stopping necessarily at VLR199 as our approach going forward. We think there is something about the way the activin trap works there that is really important to replicate the pharmacology, but also potential ways to improve moving forward. Your next generation approaches, VLR247 and VLR258, really try to maintain what we know is important for efficacy with SOTA, while decreasing some of the inhibition with what we think is causing the heme changes, specifically BMP-9 and 10. So VLR247 is based on a SOTA backbone, so the ActRIIA backbone, so SOTA-like backbone, but detuning BMP-9 and 10 in order to potentially reduce the AEs that we are seeing with SOTA. VLR258 starts with a different backbone, ActRIIB. So in that way is like what 35Pharma, now owned by GSK, is doing, also detuning BMP-9 and 10. The path from SOTA to these next generation has not been straightforward.
As many people will remember, Keros came out, I think was excited that they were detuning BMP-9 and potentially not seeing the heme changes, but had a disappointment in the phase II. I think there, with cibotercept, that was being developed by then, one of the key pieces was, yes, they detuned BMP-9 specifically, but in doing that, they lost some of the activin A inhibition. That activin A inhibition is really the key piece in terms of driving at least some of the efficacy. Unknown what the other ligands are causing there, but activin A is definitely a key part of that picture. So in reducing their BMP-9 inhibition, they also reduced their activin A inhibition too, which could have led to some of the efficacy disappointment that was seen with cibotercept. For both HS235 as well as VLR258, we are detuning both BMP-9 and 10.
We think that's really important, but maintaining that activin A inhibition too, so really getting to a better next-generation product. VLR247 will be similar to that pharmacology, but really starting with this backbone of SOTA that we know is important as well. We're also taking orthogonal approaches in PAH as well. We think this is important for the pipeline, both as a monotherapy, but also as combination. VLR360 specifically is targeting PDGFB. This is really based on what we've seen with the imatinib data. Imatinib, now a while ago, but came out with really strong PH data. What they saw was really not a tolerable drug for PAH, with discontinuations with almost a third of patients, really leading that to not moving forward. People have taken different approaches to imatinib now, primarily trying to improve the AE profile by delivering it directly to the lungs.
I think the trade-off we've seen there with most datasets is they've also lost efficacy as well. It has definitely been more tolerable, but probably an efficacy hit as well too. We think one of the reasons for that too is you need to probably deliver the drug systemically to have the maximal effect overall. Based on what we've seen from imatinib data, PDGFB specifically seems to be the driver of efficacy for imatinib, but not necessarily the driver of the safety profile that was seen. Regeneron is also developing a product here as well, so targeting very similar way to Regeneron, but doing an extended half-life version of it as well. Again, we think that has potential both in monotherapy, but as a combination approach since it's orthogonal to the SOTA mechanism as well.
Right, so activin A inhibition and the remodeling with the ligand trap and PDGFB are really working on two different parts of what could be leading to pulmonary vascular remodeling too. We think this combination approach is really important for the next generation of development for PAH. Part of what is really important in terms of what we're doing and thinking about at Velaris as well as what's been thought about at previous spin-outs from Paragon too is we're thinking about and intentionally designing these products from the beginning to be combinable moving forward. I think that others have learned over time that you can't just go grab a bunch of things off the shelf and hope they all mix well together. You have to be really intentional about how you design them and how you formulate them to have that combinability later too.
We think that's an important part of our portfolio design here and what we're trying to do with the full pipeline, not just the individual products.
I think very exciting 2027 coming up for us, where we will enter the clinic with our co-leads, VLR199 and also VLR360, the activin and the PDGFB drugs respectively. Those will then have POC data in 2028. I think, right, when we think about the overall pipeline as well, advancing those BMP-9/10 variant approaches, the IND quickly thereafter. Alongside our internal catalyst, what is exciting is, right, precedent molecules, first generations are advancing and generating additional data that we will be able to learn from. Merck, of course, has, they just put out the phase II data in heart failure, which really opens up a market up to 10x the size of PAH. GSK is advancing a BMP-9/10 variant approach, HS235, which is similar to our program VLR258. They are going to have PAH data and heart failure data over the next 12-24 months, they have said.
Both trials are ongoing concurrently. They just upsized those studies, which, right, read into that what you will. Regeneron, of course, with that phase II is ongoing in PAH, we would have a half-life extended version of that antibody. So we are looking forward to their data in 2028. We did a $350 million financing in the last month, and that gives us runway into 2029 and all the catalysts that you see here. Lastly, right, the team, many of us, we have all worked together in the past, either at Apogee and/or BridgeBio. So, strong history of operationalizing and developing drugs across the spectrum. So excited to now be taking that to Velaris and some of the largest, highest unmet need markets that we have worked on. Thanks. Enjoy your seven minutes back.
Seven days.